Home / Sweden / Oncopeptides AB
Oncopeptides AB
Short position disclosed on August 11, 2026.
1.87% of the capital sold short
2 disclosing funds
437 disclosures on record
SE0009414576 ISIN code
Evolution of the disclosed total
0%1%2%3%
Oct 2025Jan 2026Apr 2026Jul 2026
July 23, 2018 today
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| GSA Capital Partners LLP | 1.30% | new | August 11, 2026 | |
| Two Sigma Investments, LP | 0.57% | new | July 3, 2026 |
On the other side: the funds that hold Oncopeptides AB Titelia
History of disclosures
| Date | Fund | % of capital | End of publication |
|---|---|---|---|
| August 11, 2026 | GSA Capital Partners LLP | 1.30% | still open |
| July 28, 2026 | GSA Capital Partners LLP | 1.21% | still open |
| July 22, 2026 | GSA Capital Partners LLP | 1.11% | still open |
| July 16, 2026 | GSA Capital Partners LLP | 1.03% | still open |
| July 10, 2026 | GSA Capital Partners LLP | 0.92% | still open |
| July 3, 2026 | GSA Capital Partners LLP | 0.81% | still open |
| July 3, 2026 | Two Sigma Investments, LP | 0.57% | still open |
| June 26, 2026 | GSA Capital Partners LLP | 0.70% | still open |
| June 22, 2026 | GSA Capital Partners LLP | 0.60% | still open |
| June 12, 2026 | Two Sigma Investments, LP | 0.68% | still open |
| June 12, 2026 | GSA Capital Partners LLP | 0.50% | still open |
| June 8, 2026 | Two Sigma Investments, LP | 0.78% | still open |
| June 5, 2026 | Two Sigma Investments, LP | 0.82% | still open |
| May 29, 2026 | Two Sigma Investments, LP | 0.98% | still open |
| May 28, 2026 | Two Sigma Investments, LP | 0.82% | still open |
| May 27, 2026 | Two Sigma Investments, LP | 0.73% | still open |
| May 25, 2026 | Two Sigma Investments, LP | 0.62% | still open |
| May 21, 2026 | Two Sigma Investments, LP | 0.75% | still open |
| March 24, 2026 | Guevoura Fund | 1.37% | still open |
| March 20, 2026 | Guevoura Fund | 1.50% | still open |
| March 19, 2026 | Guevoura Fund | 1.49% | still open |
| March 18, 2026 | Guevoura Fund | 1.87% | still open |
| March 17, 2026 | Guevoura Fund | 1.33% | still open |
| March 16, 2026 | Guevoura Fund | 0.81% | still open |
| March 12, 2026 | Guevoura Fund | 0.54% | still open |
| January 16, 2026 | Citadel Securities (Europe) Limited | 0.65% | still open |
| September 22, 2025 | Brummer Multi-Strategy AB | 1.02% | still open |
| September 10, 2025 | Guevoura Fund | 0.56% | still open |
| August 26, 2025 | Brummer Multi-Strategy AB | 1.24% | still open |
| August 22, 2025 | Brummer Multi-Strategy AB | 1.02% | still open |
| August 21, 2025 | Brummer Multi-Strategy AB | 0.64% | still open |
| August 6, 2025 | Brummer Multi-Strategy AB | 0.72% | still open |
| August 4, 2025 | Brummer Multi-Strategy AB | 1.37% | still open |
| August 1, 2025 | Brummer Multi-Strategy AB | 0.82% | still open |
| August 27, 2024 | Citadel Securities (Europe) Limited | 0.56% | still open |
| August 23, 2024 | Citadel Securities (Europe) Limited | 0.64% | still open |
| August 14, 2024 | Citadel Securities (Europe) Limited | 0.74% | still open |
| August 12, 2024 | Citadel Securities (Europe) Limited | 0.50% | still open |
| May 16, 2024 | Guevoura Fund | 0.75% | still open |
| May 15, 2024 | Guevoura Fund | 0.67% | still open |
| May 15, 2024 | Millennium Capital Partners LLP | 0.62% | still open |
| May 7, 2024 | Millennium Capital Partners LLP | 1.23% | still open |
| April 30, 2024 | Millennium Capital Partners LLP | 1.12% | still open |
| April 29, 2024 | Millennium Capital Partners LLP | 0.98% | still open |
| April 26, 2024 | Millennium Capital Partners LLP | 0.75% | still open |
| April 25, 2024 | Millennium Capital Partners LLP | 0.58% | still open |
| March 1, 2023 | Voleon Capital Management LP | 0.68% | still open |
| February 24, 2023 | Voleon Capital Management LP | 0.76% | still open |
| February 21, 2023 | Voleon Capital Management LP | 0.88% | still open |
| February 17, 2023 | Voleon Capital Management LP | 0.98% | still open |
Other companies sold short in Sweden
- Samhällsbyggnadsbolaget i Norden AB 12.36% of the capital sold short
- Elekta AB (publ) 10.19% of the capital sold short
- JM AB 7.01% of the capital sold short
- Hemnet Group AB (publ) 6.08% of the capital sold short
- Bonesupport Holding AB 5.58% of the capital sold short
- Truecaller AB 5.43% of the capital sold short
- Embracer Group AB 5.25% of the capital sold short
- Xvivo Perfusion Aktiebolag 4.91% of the capital sold short
- Tobii AB 4.34% of the capital sold short
- Dynavox Group AB 4.30% of the capital sold short
- RaySearch Laboratories AB (publ) 4.15% of the capital sold short
- Svenska Cellulosa Aktiebolaget SCA 3.77% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Oncopeptides AB, source Finansinspektionen, data as at August 11, 2026, https://www.quivad.com/action/oncopeptides-ab